Mechanism of Action of CAR T Cells in Autoimmune Disorders
CAR T cells in autoimmune diseases work by targeting and depleting pathogenic B cells (primarily through CD19 targeting), eliminating autoreactive plasma cells, and inducing profound immune system reset that restores immune tolerance and achieves drug-free remission. 1, 2
Core Mechanism: Targeted B Cell Depletion and Immune Reset
The fundamental mechanism differs from cancer applications in its goal—rather than simply killing malignant cells, CAR T therapy in autoimmunity aims to "precision immune remodeling" rather than traditional "killing" strategies 3. Here's how this works:
Primary Cellular Targets
- CD19+ B cells: The most common target, leading to efficient depletion of autoreactive B cells that produce pathogenic autoantibodies 4, 1
- Plasma cells: Through B-cell maturation antigen (BCMA) targeting, eliminating the cells that produce autoantibodies 3
- Autoreactive T cells: Emerging as secondary targets for diseases with T cell-mediated pathology 2
The Immune Reset Process
The therapeutic effect extends beyond simple cell depletion. CAR T cells induce:
- Deep B cell depletion: Removes the pathogenic B cell population producing autoantibodies
- Immune microenvironment remodeling: Profound changes in the inflammatory milieu 3
- Restoration of immune homeostasis: Re-establishment of immune tolerance mechanisms 4
- Long-term remission: Patients achieve drug-free remission even after B cell reconstitution, suggesting fundamental immune reprogramming 1, 5
Advanced Mechanisms: Next-Generation Approaches
Chimeric Autoantibody Receptors (CAARs)
A more precise approach uses chimeric autoantibody receptors that selectively target only autoantigen-specific B cells rather than all B cells 1, 2. This provides:
- Greater specificity by targeting only pathogenic B cells
- Preservation of protective immunity
- Reduced risk of infections from pan-B cell depletion
Regulatory T Cell-Based CARs
Engineering regulatory T cells (Tregs) with CARs enables targeted immune modulation rather than depletion 4, 1. These CAR-Tregs:
- Migrate to sites of autoimmune inflammation
- Suppress local autoreactive responses
- Promote long-term tolerance without broad immunosuppression
Clinical Evidence of Mechanism
Early clinical trials demonstrate the mechanism's effectiveness:
- Systemic lupus erythematosus (SLE): CD19-targeted CAR T cells achieve significant B cell depletion with clinical improvement and drug-free remission 5
- Systemic sclerosis and inflammatory myopathies: Similar B cell depletion correlates with clinical benefit 5
- Multiple sclerosis and type 1 diabetes: Feasibility demonstrated in targeting autoreactive immune cells 4, 6
Critical Distinction from Cancer Applications
The mechanism in autoimmunity differs fundamentally:
- Goal: Immune reset and tolerance restoration, not permanent cell elimination
- Duration: Temporary depletion sufficient; immune reconstitution is actually desired
- Persistence: Lower CAR T cell persistence may be acceptable or even preferable 1
- Toxicity tolerance: Lower acceptable toxicity threshold compared to cancer 5
Important Caveats
Antigen escape remains a theoretical concern—if pathogenic B cells downregulate CD19, they could evade therapy 4, 3. However, this appears less problematic than in cancer.
Immune reconstitution after B cell depletion is critical—the quality of reconstituted B cells determines whether tolerance is restored or disease recurs 3.
Cytokine release syndrome (CRS) occurs but generally at lower severity than in cancer applications, likely due to lower tumor burden equivalent 5.